So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic.McBride, Ali; Alrawashdh, Neda; MacDonald, Karen; Abraham, Ivo researched the compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)( cas:41575-94-4 ).Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II).They published the article 《Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients》 about this compound( cas:41575-94-4 ) in Future Oncology. Keywords: pegfilgrastim anticancer agent breast cancer population; biosimilar; breast cancer; cost-efficiency; expanded access; febrile neutropenia; neutropenia; pegfilgrastim; prophylaxis. We’ll tell you more about this compound (cas:41575-94-4).
To estimate cost-savings from conversion to biosimilar pegfilgrastim-cbqv that could be reallocated to provide budget-neutral expanded access to AC (doxorubicin/cyclophosphamide) and TCH (docetaxel/carboplatin/trastuzumab) in breast cancer (BC) patients. Simulation modeling in panels of 20,000 BC and 5000 HER2+ (HER2+ BC) patients, varying treatment duration (one-six cycles) and conversion rates (10-100%), to estimate cost-savings and addnl. AC and TCH treatment that could be provided. In 20,000 patients, cost-savings of 1,083 per-patient per-cycle translate to 21,652,064 (one cycle) to 129,912,397 (six cycles). Savings range from 5,413,016 to 32,478,097, resp., in the 5000-patient HER2+ BC panel. Conversion to pegfilgrastim-cbqv could save up to 130 million and provide more than 220,000 addnl. cycles of antineoplastic treatment on a budget-neutral basis to BC patients. Pegfilgrastim is used to prevent low white blood cell count in patients receiving chemotherapy. Comparable to a generic version of a drug, a biosimilar is a follow-on version of a biol. treatment. We calculated the savings from using biosimilar pegfilgrastim in a hypothetical group of 20,000 patients with breast cancer receiving chemotherapy with AC (doxorubicin/cyclophosphamide). We then computed the number of addnl. doses of AC chemotherapy that could be purchased with those savings. We did the same for a group of 5000 HER2+ breast cancer patients treated with TCH (docetaxel/carboplatin/trastuzumab). Using biosimilar pegfilgrastim could save 1,083 per patient per cycle. If all patients were treated with biosimilar pegfilgrastim over six cycles, 129.9 million could be saved in the AC group and 32.5 million in the TCH group. This could provide 220,468 addnl. AC doses and 6981 TCH doses. Biosimilar pegfilgrastim can generate significant savings. These savings can be used to provide addnl. patients with chemotherapy cost-free.
This compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) was discussed at the molecular level, the effects of temperature and reaction time on the properties of the compound were discussed, and the optimum reaction conditions were selected.
Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics